Publications

2021 Publications

RGS4 negatively modulates Nociceptin/Orphanin FQ opioid receptor signaling: implication for L-Dopa-induced dyskinesia.
Pisanò CA, Mercatelli D, Mazzocchi M, Brugnoli A, Morella I, Fasano S, Zaveri NT, Brambilla R, O'Keeffe GW, Neubig RR, Morari M.
Br J Pharmacol. 2021 Nov 12. doi: 10.1111/bph.15730. Online ahead of print.
PMID: 34767639
 
NME1 Protects Against Neurotoxin-, α-Synuclein- and LRRK2-Induced Neurite Degeneration in Cell Models of Parkinson's Disease.
Anantha J, Goulding SR, Tuboly E, O'Mahony AG, Moloney GM, Lomansey G, McCarthy CM, Collins LM, Sullivan AM, O'Keeffe GW.
Mol Neurobiol. 2021 Oct 8. doi: 10.1007/s12035-021-02569-6. Online ahead of print.
PMID: 34623600
 
LMK235, a small molecule inhibitor of HDAC4/5, protects dopaminergic neurons against neurotoxin- and α-synuclein-induced degeneration in cellular models of Parkinson's disease.
Mazzocchi M, Goulding SR, Wyatt SL, Collins LM, Sullivan AM, O'Keeffe GW.
Mol Cell Neurosci. 2021 Sep;115:103642. doi: 10.1016/j.mcn.2021.103642. Epub 2021 Jun 10.
PMID: 34119632
 
Quinacrine and Niclosamide Promote Neurite Growth in Midbrain Dopaminergic Neurons Through the Canonical BMP-Smad Pathway and Protect Against Neurotoxin and α-Synuclein-Induced Neurodegeneration.
Goulding SR, Lévesque M, Sullivan AM, Collins LM, O'Keeffe GW.
Mol Neurobiol. 2021 Jul;58(7):3405-3416. doi: 10.1007/s12035-021-02351-8. Epub 2021 Mar 12.
PMID: 3371301
 
Growth differentiation factor 5 exerts neuroprotection in an α-synuclein rat model of Parkinson's disease.
Goulding SR, Concannon RM, Morales-Prieto N, Villalobos-Manriquez F, Clarke G, Collins LM, Lévesque M, Wyatt SL, Sullivan AM, O'Keeffe GW.
Brain. 2021 Mar 3;144(2):e14. doi: 10.1093/brain/awaa367.
PMID: 33253375

Parkinson's Disease Research Cluster (PDRC)

College of Medicine & Health, University College Cork, Ireland.

Top